| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-100957A |
| M.Wt: | 604.69 |
| Formula: | C31H44N2O10 |
| Purity: | >98 % |
| Solubility: |
Dilazep is a GATA2 inhibitor and an hENT1-mediated nucleoside transport inhibitor. Dilazep acts by blocking GATA2 chromatin recruitment and DNA binding, reducing GATA2 thermal stability, and inhibiting AR, c-MYC, the cell cycle, DNA replication/repair, and metastatic transcriptional programs; it also inhibits Adenosine (HY-B0228) reuptake and cardiac adenosine uptake, enhancing adenosine-induced coronary vasodilation. Dilazep can be used in research on atherosclerosis, ischemic heart disease, and castration-resistant prostate cancer[1][2][3][4][5][6][7].
In Vitro:Dilazep (50-100 µM; 16 hours) reduces GATA2 DNA binding in LNCaP nuclear extracts[6].
Dilazep (96 hours) inhibits the viability of GATA2-dependent LNCaP, LAPC4, Abl, 22Rv1, and MDVR prostate cancer cells, with lower activity in PC-3 and RWPE-1 cells[6].
Dilazep (50 µM; 48 hours) inhibits GATA2-, AR-, c-MYC-, cell cycle-, DNA repair-, stemness-, and metastasis-related transcriptional programs in LNCaP, Abl, and MDVR cells[6].
Dilazep (1-10 μM; from 5 minutes before ischemia to the end of 15-minute ischemia) reduces pre-ischemic RPP at 5 and 10 μM in isolated working rat hearts, but has no such effect at 1 μM, does not alter coronary flow, and improves post-ischemic recovery of RPP and coronary flow after 15-minute ischemia and 20-minute reperfusion[5].
Dilazep (20-50 µM; 24 hours) reduces S-phase entry in 22Rv1 and LNCaP cells[6].
Dilazep (1-10 μM; from 5 minutes before ischemia to the end of 15 minutes of ischemia) attenuates reperfusion-induced free fatty acid accumulation at 1, 5, and 10 μM in isolated working rat hearts, with 10 μM also reducing post-ischemic arachidonic acid (HY-109590)[5].
Dilazep (100 μM; 10 minutes to 24 hours) suppresses PpET-1 transcription to 0.04 normalized units at 24 h in subconfluent serum-treated BAEC and suppresses ET-1 peptide release to 38.8 pg/mL at 24 h[3].
Dilazep (12-24 hours) suppresses PpET-1 transcription to 0.47 at 12 hours in confluent serum-treated BAEC and suppresses ET-1 peptide release to 955.5 pg/mL at 12 hours[3].
Dilazep (1-100 μM; 16 hours) inhibits PpET-1 transcription in serum-treated BAEC in a concentration-dependent manner, reaching 0.42 at 100 μM after 16 hours[3].
Dilazep (100 μM; 3-6 hours) inhibits PpET-1 transcription to 0.41 at 3 hours and ET-1 peptide release to 299.0 pg/mL at 3 hours in serum-treated HUVECs[3].
Dilazep (100 μM; 0-4 hours) suppresses PpET-1 transcription to 0.30 at 1 hour and 0.08 at 2 hours in serum-deprived BAEC stimulated with Thrombin (MW 37kDa) (HY-114164)[3].
Dilazep (100 μM; 24 hours) inhibits ET-1 promoter activity by 99% at 24 hours in BAEC transfected with the 5-kb ET-1 promoter-luciferase construct[3].
Dilazep (1-10 μM; from 5 minutes before ischemia to the end of 15 minutes of ischemia) preserves ATP and CrP and reduces Lactic acid (HY-B2227) at 5 and 10 μM, but not at 1 μM, in isolated working rat hearts after 15 minutes of ischemia and 20 minutes of reperfusion[5].
Dilazep (1 nM-100 μM; ≥ 5 minutes) inhibits Uridine (HY-B1449) equilibrium exchange in erythrocytes, with an IC50 ≈ 7 nM in human erythrocytes, ≈ 20 nM in porcine erythrocytes, ≈ 30 nM in rabbit erythrocytes, ≈ 40 nM in mouse erythrocytes, and ≈ 1000 nM in rat erythrocytes[4].
Dilazep (50 µM; 48 hours) reduces AR, c-MYC, EZH2, RRM2, phosphorylated Rb, BRCA1, and CHK2 protein levels in LNCaP, Abl, and MDVR cells[6].
Dilazep (1 nM-100 μM; ≥ 5 min) inhibits zero-trans influx of uridine in cultured cells, with IC50 ≈ 5 nM in Hep-2, 5/3000 nM in HeLa, ≈ 10-30 nM in mouse L1210/P388/S49, ≈400 to >10000 nM in rat NRK/HTC/Novikoff/Walker 256, 20 nM in BHK, and 1000 nM in CHO cells[4].
Dilazep (10-50 µM; 72 hours) reduces AR and c-MYC protein levels in LNCaP, 22Rv1, and LAPC4 cells[6].
Dilazep (50 µM; 1 hour) binds to GATA2 in 22Rv1 cells, producing thermal destabilization with a Tm of 64-67°C[6].
Dilazep (10 µM; 16 hours) reduces GATA2 occupancy at the KLK3/PSA and c-MYC loci in LNCaP cells without reducing GATA2 protein[6].
Dilazep (10 µM; 24 hours) reduces GATA2-dependent PSA/KLK3 reporter activity in 22Rv1 cells[6].
Dilazep (10 μM; 4 days) blocks adenosine-rescued growth of wild-type hENT1 in hENT1-expressing W303-1A yeast, but has no such effect on the L92P mutant[7].
Dilazep (0.01-1000 nM; 20-minute preincubation, 20-minute uptake) inhibits [3H]adenosine transport, with an IC50 of 0.74 nM for wild-type hENT1 and an IC50 of 2.8 nM for L92Q in hENT1-expressing YPL1 yeast[7].
In Vivo:Dilazep (50 mg/kg; i.p.; daily 5 days per week (Monday-Friday)) inhibits MDA-PCa-337A castration-resistant prostate cancer PDX tumor growth in castrated SCID mice without causing body-weight loss[6].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.